Value-Added Schizophrenia Round-Up: Luye Expects Chinese First With US Risperidone

 
• By Aidan Fry

Several firms are making progress on added-value risperidone formulations: Luye Pharma anticipates FDA approval for its extended-release microspheres; Rovi is moving towards a US 505(b)(2) filing for its Doria once-monthly formulation; and Indivior has introduced its Perseris subcutaneous suspension in the US.

ValueAdded
Several companies are making progress on developing and launching added-value schizophrenia treatments • Source: Shutterstock

More from Value Added Medicines

More from Products